960503-83-7

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 34813-49-5 t-butylsulfonamide 
• 146374-27-8 S-tert-butylsulfinimide 

Downstream Products

• 53848-00-3 5-(3-bromophenyl)-1H-imidazole 
• 960526-58-3 3-[8-(3-bromophenyl)-3,3-difluoro-6-thioxo-2,3,4,6,7,8-hexahydroimidazo[1,5-a]pyrimidin-8-yl]-N,N-dimethylbenzamide 
• 960526-56-1 3-[4-(3-bromophenyl)-2,5-dithioxo-1,3-thiazolidin-4-yl]-N,N-dimethylbenzamide 
• 960526-54-9 3-[(3-bromophenyl)(isothiocyanato)methyl]-N,N-dimethylbenzamide 
• 960526-52-7 3-[amino(3-bromophenyl)methyl]-N,N-dimethylbenzamide 
• 960526-83-4 C₂₀H₂₅BrN₂O₂S 

Relevant academic research and scientific papers

TMSOTf-mediated synthesis of skipped dienes through the addition of olefins to imines and semicyclicN,O-acetals

A novel approach to skipped dienes has been developed through the TMSOTf-mediated one-pot addition-substitution of olefins2a,2fand2gwith imines1a-1g, and a series of aryl substituted skipped dienes3aa-3gfwere accordingly obtained in 62%-94% yields. Moreov

NOVEL NON-SYSTEMIC TGR5 AGONISTS

The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.